In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
Clinical Report: GLP-1 Drugs Tied to Lower Addiction Risk
Overview
A large observational study found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with lower risks of substance use disorders (SUDs) among US veterans with type 2 diabetes. However, the findings do not support prescribing GLP-1 RAs specifically for SUD treatment. The findings suggest potential benefits in selecting antihyperglycemic therapy for patients at elevated risk for SUDs.
Background
Substance use disorders pose significant health risks and are prevalent among individuals with diabetes. Understanding the relationship between diabetes medications and SUDs is crucial for optimizing treatment strategies. This study provides insights into how GLP-1 RAs may influence addiction-related outcomes in a high-risk population.
Data Highlights
Outcome
Hazard Ratio (HR)
Cases per 1,000 patients over 3 years
Composite SUDs
0.86
7 fewer
Alcohol use disorder
0.82
5-6 fewer
Cannabis use disorder
0.86
Not specified
Cocaine use disorder
0.80
1 fewer
Nicotine use disorder
0.80
1 fewer
Opioid use disorder
0.75
1 fewer
SUD-related emergency visits
0.69
12 fewer
SUD-related hospital admissions
0.74
12 fewer
SUD-related mortality
0.50
12 fewer
Key Findings
GLP-1 RA initiation was associated with a lower risk of incident SUDs (HR, 0.86).
Lower risks were observed for specific SUDs: alcohol (HR, 0.82), cannabis (HR, 0.86), cocaine (HR, 0.80), nicotine (HR, 0.80), and opioids (HR, 0.75).
Among patients with pre-existing SUDs, GLP-1 RA initiation correlated with fewer SUD-related emergency department visits (HR, 0.69) and hospital admissions (HR, 0.74).
GLP-1 RA use was linked to a significant reduction in SUD-related mortality (HR, 0.50).
Findings reflect relative comparisons with SGLT-2 inhibitors, not placebo.
Observational nature of the study suggests caution due to potential confounding factors.
Clinical Implications
Healthcare professionals should consider the potential benefits of GLP-1 RAs in patients with type 2 diabetes who are at risk for substance use disorders. However, these medications should not be prescribed specifically for SUD treatment without further evidence from randomized controlled trials.
Conclusion
The study highlights a potential role for GLP-1 receptor agonists in reducing the risk of substance use disorders among patients with type 2 diabetes, warranting further investigation into their therapeutic applications.
Longitudinal cohort data linked bullying and persistently unsupportive state gender-identity policies with worsening psychotic-like experiences among gender-diverse youths.
